Therapeutic efficacy of Avigan against COVID-19 infection

Abstract

The characteristics of COVID-19 infection consist of the characteristics of both influenza caused by infection-induced cytokines and varicella caused by cell-mediated immunity to the virus. An indicator of the therapeutic efficacy of anti-herpetic drugs in herpes zoster is the cessation of new lesions rather than the improvement of inflammation. Inflammation due to cell-mediated immunity reaches its peak 3 days after antigen contact in lacquer dermatitis. Therefore, the inflammation due to cell-mediated immunity in herpes zoster worsens for 3-5 days due to the persistent presence of the virus even after the start of antiviral treatment. It is a characteristic of COVID-19 pneumonia that Avigan (favipiravir) treatment is effective but that the inflammation of COVID-19 pneumonia continues to worsen for 3-5 days even after Avigan treatment.